Skip to main content
ACR Convergence 2023 Main banner
Final Program


Schedule at a Glance
Legend
Session Format
In Person
In Person
Livestreamed
Livestreamed
On Demand
On Demand
Back
Scientific Session

Osteoarthritis (OA) and related disorders
General Topic: Clinical Science

12S103: Controversies and Updates in Osteoporosis Management

Sunday, November 12, 2023
7:30 AM – 8:30 AM PT
Location: Room 6A-B
CE: 1

On Demand In Person Livestreamed

    Speaker(s)

  • BL

    Bente Langdahl, MD, PhD

    Aarhus University Hospital
    Aarhus N, Denmark

    Disclosure(s): Amgen: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Astellas: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); AstraZeneca: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Gedeon-Richter: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Novo Nordic Foundation: Grant/Research Support (Ongoing); Samsung Bioepis: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); UCB: Advisor or Review Panel Member (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

  • CW

    Connie Weaver, PhD, MS

    San Diego State University
    San Diego, CA, United States

    Disclosure(s): No financial relationships with ineligible companies to disclose

    • Virtual Speaker(s)

  • RE

    Richard Eastell, MD, FRCP

    University of Sheffield
    Sheffield, United Kingdom

    Disclosure(s): Alexion: Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Amgen: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, May 31, 2022); Biocon: Consultant (Ongoing); CL Bio: Consultant (Ongoing), Grant/Research Support (Ongoing); Immunodiagnostic Systems: Consultant (Ongoing), Grant/Research Support (Ongoing); Pharmacosmos: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Samsung Bioepis: Consultant (Ongoing); Sandoz: Consultant (Terminated, November 30, 2022); Takeda: Consultant (Terminated, August 31, 2022); UCB: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, April 14, 2023)

Osteoporosis and fragility fracture is an ever-increasing public health problem due to our aging population. US data suggests that once over the age of 50, one in two women and up to one in four men will suffer an osteoporotic fracture. Despite well-established methods for screening and diagnosing osteoporosis, as well as a number of FDA-approved therapies for treatment, there remains a number of unanswered questions. This session will focus on common dilemmas in day-to-day management of osteoporosis, including monitoring with markers,

Learning Objectives:

  • Identify strategies to safety transition a patient from denosumab to an alternative osteoporosis therapy safely
  • Illustrate situations where the use of bone turnover markers can assist in the management of osteoporosis
  • Address when to follow 25-hydroxyvitamin D levels and how to manage vitamin D status in light of the VITAL Study Results

Presentations:

  • 7:30 AM – 7:45 AM PT
    Life After Denosumab: How and What to Transition to Next?

    Speaker: Bente Langdahl, MD, PhD – Aarhus University Hospital

  • 7:45 AM – 8:00 AM PT
    Bone Turnover Markers: Ready for Prime Time

    Virtual Speaker: Richard Eastell, MD, FRCP – University of Sheffield

  • 8:00 AM – 8:15 AM PT
    Update on Vitamin D: Supplementation and Monitoring

    Speaker: Connie Weaver, PhD, MS – San Diego State University

  • 8:15 AM – 8:30 AM PT
    Q&A